# Freenome licenses its colorectal blood test to Exact Sciences in a deal worth up to $885M

Canonical page: https://technooptimist.io/stories/freenome-licenses-its-colorectal-blood-test-to-exact-sciences-in-a-deal-5f1df735
Date: 6 Aug 2025
About: [Freenome](https://technooptimist.io/companies/freenome.md) · [SimpleScreen CRC](https://technooptimist.io/biotech/simplescreen-crc.md)
Original source: https://www.freenome.com/newsroom/freenome-announces-exclusive-license-agreement-with-exact-sciences-to-commercialize-freenomes-blood-based-screening-test-for-colorectal-cancer/

Freenome gave Exact Sciences, maker of the Cologuard stool test, exclusive rights to sell its blood-based colorectal screening test, and submitted the final module of its FDA application. In the 48,995-person PREEMPT CRC study, the test caught 81.1% of colorectal cancers with 90.4% specificity. Freenome keeps the right to sell the test bundled with its future multi-cancer screens.

## Key facts

- $75M upfront, $200M tied to FDA approvals, $500M if USPSTF rates it A or B, royalties ramping to 10%.
- Stage I sensitivity 63.5%; advanced precancerous lesions 13.7%.
- A next-generation version showed stronger detection and will follow as a PMA supplement.

---

The Techno Optimist tracks every frontier of technology, program by program: https://technooptimist.io/ (a Markdown version of any page: add .md to its URL; site map for agents: https://technooptimist.io/llms.txt).
Data API (JSON, realtime stream): https://technooptimist.io/developers. People read 5 pages free, then Reader $10/month; these Markdown pages are open to agents.